Alectinib in crizotinib-resistant, ALK-positive NSCLC
Mené sur 87 patients atteints d'un cancer du poumon non à petites cellules ALK+ de stade IIIB-IV ayant progressé après un traitement par crizotinib, cet essai de phase II évalue l'efficacité, du point de vue du pourcentage de patients avec une réponse objective, et la toxicité de l'alectinib
The discovery of molecular drivers of carcinogenesis has resulted in a large-scale shift in thinking about cancer treatment. Advanced non-small-cell lung cancer (NSCLC)—once judged a fairly homogenous entity and managed uniformly with chemotherapy—is now perceived as a conglomerate of various molecular subtypes that need different treatments. Rearrangements of the ALK oncogene are among the most intensively investigated molecular targets in NSCLC. ALK-rearranged (ALK-positive) disease comprises about 4–5% of all cases of NSCLC and is characterised by frequent metastatic spread to the pericardium, pleura, liver, and CNS.
The Lancet Oncology 2015